Welcome to our dedicated page for Attovia Therapeutics SEC filings (Ticker: ATTO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Attovia Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Attovia Therapeutics's regulatory disclosures and financial reporting.
Attovia Therapeutics, Inc. (ATTO) reported unaudited results for the quarter and six months ended June 30, 2026, reflecting continued investment in its immune‑mediated disease pipeline and preparations for becoming a public company. For the first half of 2026, revenue was $0.45 million from a collaboration with EndPath, while operating expenses rose to $42.2 million, driven by $35.7 million of research and development spending and $6.5 million of general and administrative costs.
This produced a first‑half net loss of $39.3 million, compared with $29.6 million a year earlier, and an accumulated deficit of $150.4 million as of June 30, 2026. Cash, cash equivalents and marketable securities totaled $115.1 million at quarter‑end. Subsequent to the period, Attovia completed an IPO raising approximately $305.4 million in net proceeds and effected a 1‑for‑9.29 reverse stock split, with all share and per‑share data retrospectively adjusted. Management states that existing cash, cash equivalents and marketable securities together with IPO proceeds are expected to fund planned operations into 2030.
Attovia Therapeutics, Inc. (ATTO) reported second quarter 2026 results and a corporate update, highlighted by preliminary clinical proof of concept for lead candidate ATTO-1310 in chronic pruritus and high-itch atopic dermatitis, showing rapid, deep itch relief and lesion control in a Phase 1b study.
The company plans two global Phase 2 trials of ATTO-1310 in chronic pruritus of unknown origin and high-itch atopic dermatitis, both targeted to start in the first half of 2027, and is advancing ATTO-2306 and ATTO-1091 toward Phase 1 initiation in the same timeframe. Early program ATTO-006 is being moved toward development candidate nomination by year-end 2026.
Attovia completed an upsized IPO with $332.4 million in gross proceeds and expects that existing cash, cash equivalents and marketable securities, including $305.4 million of IPO net proceeds, will fund operations into 2030. For the quarter ended June 30, 2026, collaboration revenue was $0.5 million, research and development expenses were $18.9 million, and net loss was $20.7 million. Cash, cash equivalents and marketable securities were $115.1 million as of June 30, 2026, prior to the August IPO.
Attovia Therapeutics, Inc. (ATTO) is the issuer in a Notice of Proposed Sale of Securities on Form 144 filed in connection with planned sales of its common stock by Goldman Sachs Group Inc., identified as a former 10% owner. The notice covers up to 105,807 shares of Attovia common stock. The shares to be sold were acquired through securities borrowing by Goldman Sachs & Co. LLC, which is acting as a market maker in the ordinary course of business, and trades may occur on CBOE, IEX, MEMX and Nasdaq. The Form 144 is a resale notice for the selling party; Attovia does not sell shares or receive proceeds in this transaction.
Attovia Therapeutics, Inc. (ATTO) is the subject of an amended Form 4 reporting complex indirect transactions associated with director Colin Walsh and entities affiliated with The Goldman Sachs Group Inc. Series B and C Preferred Stock automatically converted into common stock at a 9.29-for-1 ratio upon the IPO closing on August 6, 2026, eliminating those preferred holdings. Goldman Sachs & Co. LLC, acting as a market maker, reported purchases and sales of common stock and the establishment of long equity swap positions, with any profit potentially recoverable under Section 16(b) to be remitted to Attovia. The amendment also corrects an earlier administrative error in the number of common shares issuable upon conversion, and Walsh disclaims beneficial ownership except to the extent of any pecuniary interest.
Attovia Therapeutics, Inc. (ATTO) reported insider activity by multiple Goldman Sachs–affiliated entities, all listed as former 10% owners. On August 6, 2026, they reported the conversion of Series B and Series C Preferred Stock into common stock, eliminating 18,181,830 Series B and 4,445,275 Series C preferred shares and issuing 1,957,134 and 478,598 common shares, respectively. This corrects an administrative error in an earlier Form 3 and reflects automatic conversion upon the IPO after a 1‑for‑9.29 reverse stock split.
On the same date, an affiliated entity purchased 500,000 common shares at $17.00 per share. On August 5, 2026, Goldman Sachs & Co. LLC, acting as a market maker, purchased 85,000 shares, sold 105,807 shares, and entered into long equity swap positions referencing 105,807 shares at prices around $21.22–$21.27. The reporting persons disclaim beneficial ownership except to the extent of any pecuniary interest, and any Section 16(b) profit from the market‑making trades will be remitted to Attovia.
Attovia Therapeutics, Inc. director Colin Walsh, affiliated with Goldman Sachs entities, reported the automatic conversion of 22,627,105 shares of Series B and C Preferred Stock into common stock on a 9.29-for-1 basis upon the company’s IPO closing on August 6, 2026, with no cash consideration. The resulting common shares are held indirectly through multiple Goldman Sachs-managed investment vehicles, and Walsh disclaims beneficial ownership beyond any pecuniary interest. On August 5–6, 2026, Goldman Sachs & Co. LLC, acting as a market maker, purchased 585,000 ATTO common shares (including 500,000 at $17.00 and 85,000 at $21.00) and sold 105,807 shares around $21–22 per share; any profit recoverable under Section 16(b) will be remitted to Attovia.
Goldman Sachs–affiliated entities reported multiple transactions in Attovia Therapeutics common stock and preferred stock. On completion of Attovia’s IPO, all redeemable convertible preferred stock automatically converted into common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split, and prior Form 3 conversion figures were corrected. GS&Co, acting as a market maker, bought 85,000 shares and sold 105,807 shares of common stock on August 5, 2026, and additional common shares were purchased in the IPO by affiliated investment vehicles.
Deep Track Capital and affiliates report a significant ownership position in Attovia Therapeutics, Inc. The group, consisting of Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin, reports beneficial ownership of 3,207,138 shares of Attovia common stock, representing 7.45% of the outstanding class. The reporting persons have shared voting and dispositive power over all 3,207,138 shares and no sole voting or dispositive power. The ownership percentage is based on 43,029,017 shares of common stock outstanding as of August 5, 2026, as referenced from Attovia’s prospectus. David Kroin may be considered a control person of Deep Track Capital, LP, and the parties have filed a joint statement reflecting their coordinated reporting.
Attovia Therapeutics, Inc. received a large shareholder disclosure from several Frazier Life Sciences funds. Frazier Life Sciences Public Fund, L.P. reports beneficial ownership of 760,327 shares of common stock, or 1.7% of the class, based on 45,579,017 shares anticipated to be outstanding after the IPO. Frazier Life Sciences XI, L.P. reports 6,154,213 shares, or 13.5%, and Frazier Life Sciences XII, L.P. reports 54,163 shares, or 0.1%.
FLS XI acquired its position primarily through pre-IPO preferred stock and common stock purchases totaling about $59,979,760, which converted into common stock at the IPO, while FLSPF, FLS XI and FLS XII bought additional IPO shares at $17.00 per share for an aggregate $21,250,000. FLSPF and FLS XII then made follow-on open-market purchases on August 5–7, 2026 within stated price ranges.
The holdings are described as for investment purposes, with no current plans for corporate control actions. Certain Frazier funds are subject to 180‑day lock-up agreements after the IPO prospectus date and benefit from an Amended and Restated Investors' Rights Agreement providing registration rights for resales, subject to customary limitations.
Attovia Therapeutics, Inc. insider Deep Track Biotechnology Master Fund, Ltd. reported the automatic conversion of Series C Redeemable Convertible Preferred Stock into common stock in connection with the closing of Attovia’s initial public offering. 18,181,818 preferred shares converted into 1,957,138 common shares at a 9.29-for-one ratio, resulting in 1,957,138 common shares held directly. Deep Track Capital, LP and David Kroin may be deemed beneficial owners through their roles but each disclaims beneficial ownership beyond their respective pecuniary interests.